Monte Rosa Q2 2026 net loss $43.4M; cash $626M; MRT-8102 GFORCE-1 readout H2 2026

Monte Rosa Therapeutics, Inc.

Net loss of $43.4M in Q2 2026 vs $12.3M in Q2 2025; collaboration revenue $9.0M vs $23.2M.
Cash, equivalents, and marketable securities $626.0M as of June 30, 2026; expected to fund operations into 2029.
MRT-8102 GFORCE-1 study fully enrolled; readout of CRP and calprotectin data expected H2 2026.
Novartis activated Phase 2 study of MRT-6160 (DDY391) in Sjögren's disease; Monte Rosa eligible for milestone.
MODeFIRe-1 Phase 2 study of MRT-2359 in mCRPC with AR mutations activated; first patient dosing expected Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.